Prospective Phenotyping for Genetic Subtypes of Early-onset Atrial Fibrillation

Key facts

Sponsor

Vanderbilt University Medical Center

Principal Investigator

M. B Shoemaker, MD

Vanderbilt University Medical Center

Intervention

None/Observational Studies(other)

Enrollment

225 target

Eligibility

15 years · All sexes

Timeline

2022 – 2026

Study locations (1)

• Vanderbilt University Medical Center, Nashville, Tennessee, United States

Collaborators

National Heart, Lung, and Blood Institute (NHLBI)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Hereditary atrial fibrillation

Additional recruiting or active studies for the same condition.

• RECRUITINGNANCT06578104
  PULSED AF Post-Approval Study
  Medtronic Cardiac Ablation Solutions
• RECRUITINGNANCT05951101
  Zenith LAA Occlusion System
  AuriGen Medical Ltd
• RECRUITINGPHASE3NCT04045665
  Anticoagulation for New-Onset Post-Operative Atrial Fibrillation After CABG
  Icahn School of Medicine at Mount Sinai

See all trials for Hereditary atrial fibrillation →